Trial Profile

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Capecitabine; Eribulin; Gemcitabine; Vinorelbine
Indications Advanced breast cancer; Triple negative breast cancer
Focus Registrational; Therapeutic Use
Acronyms KEYNOTE-119
Sponsors Merck Sharp & Dohme

12 Oct 2023 Results (n=187) assessing effect of pembrolizumab versus chemotherapy on prespecified health-related quality of life (HRQoL) published in the European Journal of Cancer.
04 Mar 2021 Results comparing pembrolizumab with chemotherapy for second-line or third-line treatment of patients with metastatic triple-negative breast cancer, published in the Lancet Oncology
11 Dec 2020 Results presented at the 43rd Annual San Antonio Breast Cancer Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com